Stocks · News reference

Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study

Jul 22, 2026, 11:29 AMVandana Singh

Celldex has discontinued its Phase 2 trial of barzolvolimab for prurigo nodularis after failing to meet primary and secondary endpoints.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 7, 2026, 6:52 PMBenzinga Newsdesk
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $46
Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $40 to $46.
Read original at benzinga
CLDX
BenzingaAug 7, 2026, 10:50 AMBenzinga Newsdesk
Barclays Maintains Overweight on Celldex Therapeutics, Raises Price Target to $53
Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $48 to $53.
Read original at benzinga
CLDX
BenzingaAug 6, 2026, 9:57 PMBenzinga Newsdesk
Celldex Therapeutics Q2 EPS $(0.94) Beats $(1.07) Estimate, Sales $22.000K Miss $954.444K Estimate
Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(0.94) per share which beat the analyst consensus estimate of $(1.07) by 12.15 percent. This is a 10.59 percent decrease over losses of $(0.85) per share
Read original at benzinga
CLDX
BenzingaJul 29, 2026, 4:11 PMBenzinga Newsdesk
Wells Fargo Maintains Overweight on Celldex Therapeutics, Raises Price Target to $72
Read original at benzinga
CLDX